Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
GlobeNewswire Inc.
·
1d ago
Sign in to get a one-time email the moment KLRS crosses your price. Free accounts included.
Sign in / create a free account